Holen Sie sich die Stockscreener-App
20.86
1.28%
-0.27
Schlusskurs vom Vortag:
$21.13
Offen:
$21.08
24-Stunden-Volumen:
223.31K
Relative Volume:
0.74
Marktkapitalisierung:
$846.27M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-136.98M
KGV:
-5.1891
EPS:
-4.02
Netto-Cashflow:
$-126.63M
1W Leistung:
+5.14%
1M Leistung:
+10.55%
6M Leistung:
+23.72%
1J Leistung:
-24.94%
1-Tages-Spanne:
$20.63
$21.32
1-Wochen-Bereich:
$19.15
$21.86
52-Wochen-Spanne:
$15.47
$36.37
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Firmenname
Arrivent Biopharma Inc
Sektor
Branche
Telefon
240-780-6356
Adresse
18 CAMPUS BLVD., NEWTOWN SQUARE
Vergleichen Sie AVBP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
20.86 | 857.22M | 0 | -136.98M | -126.63M | -4.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Fortgesetzt | Goldman | Buy |
| 2025-03-20 | Eingeleitet | B. Riley Securities | Buy |
| 2025-03-10 | Eingeleitet | Guggenheim | Buy |
| 2024-07-22 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-02-20 | Eingeleitet | Citigroup | Buy |
| 2024-02-20 | Eingeleitet | Goldman | Buy |
| 2024-02-20 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Arrivent Biopharma Inc Aktie (AVBP) Neueste Nachrichten
How ArriVent BioPharma Inc. stock reacts to Fed rate cutsGap Down & Free Long-Term Investment Growth Plans - newser.com
What’s the recovery path for long term holders of ArriVent BioPharma Inc.July 2025 Institutional & Weekly Breakout Watchlists - newser.com
Analyzing ArriVent BioPharma Inc. with multi timeframe chartsJuly 2025 Closing Moves & Verified Momentum Stock Ideas - newser.com
Is ArriVent BioPharma Inc. stock attractive after correctionWeekly Market Report & Low Volatility Stock Recommendations - newser.com
Should you hold or exit ArriVent BioPharma Inc. nowJuly 2025 Momentum & Accurate Trade Setup Notifications - newser.com
Can volume confirm reversal in ArriVent BioPharma Inc.July 2025 Intraday Action & AI Forecasted Entry/Exit Points - newser.com
ArriVent BioPharma (NASDAQ:AVBP) Given Sell (D-) Rating at Weiss Ratings - MarketBeat
Will ArriVent BioPharma Inc. stock see PE expansion2025 Stock Rankings & AI Forecasted Stock Moves - newser.com
ArriVent BioPharma Secures Global Rights to MRG007 in Strategic Deal with Lepu Biopharma - MSN
Is it too late to sell ArriVent BioPharma Inc.2025 Momentum Check & Fast Moving Stock Trade Plans - newser.com
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Analyzing drawdowns of ArriVent BioPharma Inc. with statistical toolsWeekly Trend Recap & Smart Money Movement Tracker - newser.com
How moving averages guide ArriVent BioPharma Inc. tradingTrade Risk Assessment & Long-Term Safe Return Strategies - newser.com
Certain Options of ArriVent BioPharma, Inc. are subject to a Lock-Up Agreement Ending on 1-OCT-2025. - MarketScreener
Certain Common Stock of ArriVent BioPharma, Inc. are subject to a Lock-Up Agreement Ending on 1-OCT-2025. - MarketScreener
ArriVent BioPharma Taps Brent S. Rice as Chief Commercial Officer - MyChesCo
ArriVent BioPharma Reports Q1 2025 Financial Results and Highlights Key Achievements - MSN
ArriVent Reports Promising Results for Firmonertinib in Lung Cancer Patients With Rare EGFR Mutations - MSN
Can S.P.E.E.H. Hidroelectrica S.A. (E28) stock hold up in economic slowdownJuly 2025 Patterns & AI Powered Market Entry Strategies - newser.com
Is it time to cut losses on ArriVent BioPharma Inc.2025 Institutional Moves & Fast Moving Market Watchlists - newser.com
Custom watchlist performance reports with ArriVent BioPharma Inc. - newser.com
Goldman Sachs Group Inc. Reduces Holdings in ArriVent BioPharma, Inc. $AVBP - MarketBeat
ArriVent BioPharma appoints Brent Rice as chief commercial officer - Investing.com
ArriVent BioPharma appoints Brent Rice as chief commercial officer By Investing.com - Investing.com Nigeria
ArriVent Appoints Brent Rice as Chief Commercial Officer - citybiz
ArriVent Biopharma appoints Brent Rice as chief commercial officer - TipRanks
Arrivent appoints Brent S. Rice as Chief Commercial Officer - MarketScreener
ArriVent BioPharma Names Brent S. Rice as CCO - MarketScreener
ArriVent BioPharma Announces Appointment of Brent S. Rice as Chief Commercial Officer - Quiver Quantitative
ArriVent Appoints Brent S. Rice as Chief Commercial Officer - The Manila Times
Oncology Biotech ArriVent BioPharma Taps 25-Year Industry Veteran to Lead Lung Cancer Drug Launch - Stock Titan
Will earnings trigger a reversal in ArriVent BioPharma Inc.Quarterly Earnings Report & Consistent Profit Trading Strategies - newser.com
Institutional scanner results for Baker Hughes CompanyTrade Signal Summary & Daily Technical Forecast Reports - newser.com
Finanzdaten der Arrivent Biopharma Inc-Aktie (AVBP)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):